Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Amgen Inc. | Tezepelumab - SOURCE | Oral corticosteroid dependent asthma. | Phase 3 | Subcutaneous | Respiratory | |
| Amgen Inc. | Tarlatamab (AMG 757) and durvalumab with durvalumab alone in first-line - (DeLLphi-305) | Small cell lung cancer (SCLC) | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Amgen Inc. | TEPEZZA (Teprotumumab) | Thyroid Eye Disease (TED) - chronic | Phase 3 | Intravenous | Opthalmic | |
| Amgen Inc. | Nplate | Chemotherapy-induced thrombocytopenia in gastrointestinal, pancreatic, or colorectal malignancies | Phase 3 | Enrollment Conclusion | Subcutaneous | Hematology |
| Amgen Inc. | Tezepelumab | Eosinophilic esophagitis (EoE) | Phase 3 | Ongoing | Subcutaneous | Gastroenterology |
| Amgen Inc. | bempikibart | Alopecia areata | Phase 2 | intravenous | Immunology | |
| Amgen Inc. | AMG 133 (maridebart cafraglutide) - (MariTide) | Obesity and without diabetes | Phase 2 | Data Released | subcutaneous | Endocrinology |
| Amgen Inc. | AMG 104 (AZD8630) | healthy volunteers and patients with asthma | Phase 2 | Trial Planned | Intravenous | Respiratory |
